Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$3.6 million.

  • Exagen's Change in Receivables fell 5695.16% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 12226.72%. This contributed to the annual value of $1.3 million for FY2024, which is 17088.61% up from last year.
  • Per Exagen's latest filing, its Change in Receivables stood at -$3.6 million for Q3 2025, which was down 5695.16% from -$1000.0 recorded in Q2 2025.
  • In the past 5 years, Exagen's Change in Receivables ranged from a high of $6.9 million in Q2 2023 and a low of -$10.5 million during Q4 2023
  • Moreover, its 5-year median value for Change in Receivables was $444000.0 (2021), whereas its average is $114842.1.
  • Per our database at Business Quant, Exagen's Change in Receivables tumbled by 112747.75% in 2022 and then soared by 41566.48% in 2023.
  • Over the past 5 years, Exagen's Change in Receivables (Quarter) stood at $444000.0 in 2021, then crashed by 1127.48% to -$4.6 million in 2022, then tumbled by 130.01% to -$10.5 million in 2023, then soared by 85.21% to -$1.6 million in 2024, then plummeted by 134.21% to -$3.6 million in 2025.
  • Its Change in Receivables stands at -$3.6 million for Q3 2025, versus -$1000.0 for Q2 2025 and $6.9 million for Q1 2025.